Antiaging Quantum Living Inc (AAQL)

[maverick_1]

Sadly despite the institutional ownership and bloodletting, yet another one that I've posted on that has fallen many stair rungs from their highs: ACHN from the low teens.

Pyrrh & his handful of other alias(ie:micheone; milner etc) is the strike out king in picking stocks..... along with being the king of narcissists and distortionist....... as belatedly acknowledge by many.

Biotecs are richly laden with land mines and science is just one of many complex facets needed to stock picking.

Disappointing mid-stage data for triple combo for HCV-3 sinks Achillion; shares down 12%

Apr. 24, 2017 3:48 PM ET|About: Achillion Pharmaceutic... (ACHN)|By: Douglas W. House, SA News Editor
Achillion Pharmaceuticals (ACHN -12.4%) is on the outside looking in at the market's and biotech's big up move today. Data presented at The International Liver Congress showed a 100% cure rate at weeks 6 and 8 for HCV genotype 1 for the triple combo of simeprevir, odalasvir and AL-335. For HCV genotype 3, though, there was not enough of an efficacy signal to warrant continued development.

The negative result in the most treatment-resistant HCV genotype has spooked investors. Baird wasted little time in adjusting its outlook, cutting the price target in half to $5 (57% upside).

Achillion's odalasvir, an NS5A inhibitor, is being developed by J&J's Janssen Pharmaceuticals under a May 2015 global agreement.

Previously: Triple combo of simeprevir, odalasvir and AL-335 produced 100% cure rate in as little as six weeks in mid-stage HCV study (April 24)

http://ir.achillion.com/releasedetail.cfm?ReleaseID=1022374